An Observational Study to Assess the Effectiveness of Intravitreal Aflibercept in Routine Clinical Practice tn Patients With Visual Impairment Due to Diabetic Macular Oedema (DMO)
Phase of Trial: Phase IV
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Sponsors Bayer
- 13 Mar 2018 Planned End Date changed from 30 Dec 2019 to 30 Jun 2020.
- 13 Mar 2018 Planned primary completion date changed from 30 Dec 2018 to 30 Mar 2019.
- 12 Dec 2017 Planned End Date changed from 30 Sep 2019 to 30 Dec 2019.